Industry Strength Score
32/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
VALERIO TX (ALVIO.PA) Stock Price & Overview
EPA:ALVIO • FR0010095596
Current stock price
0.1584 EUR
+0 (+1.67%)
Last:
The current stock price of ALVIO.PA is 0.1584 EUR. Today ALVIO.PA is up by 1.67%. In the past month the price increased by 34.24%. In the past year, price increased by 158.82%.
ALVIO.PA Key Statistics
52-Week Range0.0422 - 0.31
Current ALVIO.PA stock price positioned within its 52-week range.
1-Month Range0.113 - 0.16
Current ALVIO.PA stock price positioned within its 1-month range.
- Market Cap
- 79.113M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.09
- Dividend Yield
- N/A
ALVIO.PA Stock Performance
Today
+1.67%
1 Week
+4.21%
1 Month
+34.24%
3 Months
+11.94%
Longer-term
6 Months +77.98%
1 Year +158.82%
2 Years +46.67%
3 Years N/A
5 Years N/A
10 Years N/A
ALVIO.PA Stock Chart
ALVIO.PA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ALVIO.PA. When comparing the yearly performance of all stocks, ALVIO.PA is one of the better performing stocks in the market, outperforming 97.32% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ALVIO.PA Earnings
Next Earnings DateN/A
Last Earnings DateOct 1, 2025
PeriodQ2 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
ALVIO.PA Forecast & Estimates
Analysts
Analysts34.29
Price TargetN/A
EPS Next Y23.08%
Revenue Next YearN/A
ALVIO.PA Financial Highlights
Over the last trailing twelve months ALVIO.PA reported a non-GAAP Earnings per Share(EPS) of -0.09. The EPS increased by 27.92% compared to the year before.
Income Statements
Revenue(TTM)1.83M
Net Income(TTM)-13.17M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.42% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%98.05%
Sales Q2Q%41.57%
EPS 1Y (TTM)27.92%
Revenue 1Y (TTM)-3.12%
ALVIO.PA Ownership
Ownership
Inst Owners8.84%
Shares499.45M
Float452.35M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
ALVIO.PA Industry Overview
ALVIO.PA operates in the Biotechnology sub-industry within the Health Care sector. This group contains 51 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
77/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
16%
Outperformed 16% of sub-industries
3 Month Rank
19%
Outperformed 19% of sub-industries
6 Month Rank
36%
Outperformed 36% of sub-industries
Industry Fundamentals & Breadth
- Members
- 51
- New Highs
- 2%
- New Lows
- 11.8%
- Average ROE
- 26.9%
- Average Profit Margin
- 29.8%
- Average Operating Margin
- 26.1%
- Average P/E
- 38.5
- Average Fwd P/E
- 30.5
- Average Debt/Equity
- 0.0
ALVIO.PA Competitors/Peers
The largest stocks on the EU markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.81 | 41.543B | ||
| 1AE | ARGENX SE | 28.79 | 41.518B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.443B | ||
| ABVX | ABIVAX SA | N/A | 7.648B | ||
| 2X1 | ABIVAX SA | N/A | 7.64B | ||
| GLPG | GALAPAGOS NV | N/A | 1.591B | ||
| GXE | GALAPAGOS NV | N/A | 1.59B | ||
| NANO | NANOBIOTIX | N/A | 1.39B | ||
| PHARM | PHARMING GROUP NV | 47.29 | 1.011B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1.01B | ||
| PHGN | PHARMING GROUP NV | 47.13 | 1.008B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 954.74M | ||
| IVA | INVENTIVA SA | N/A | 895.23M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALVIO.PA
Company Profile
Valerio Therapeutics SA is a is a clinical-stage biotechnology company, which engages in the development of oncology drugs targeting tumor intracellular processes. The company is headquartered in Paris, Ile-De-France and currently employs 25 full-time employees. The company went IPO on 2005-07-12. The firm targets tumor DNA functions through unparalleled mechanisms of action in the sought-after field of DNA damage response (DDR). The company aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. The company has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. The company also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.
Company Info
IPO: 2005-07-12
VALERIO TX
49 boulevard du General Martial Valin
Paris ILE-DE-FRANCE FR
Employees: 25
Phone: 33145587600
VALERIO TX / ALVIO.PA FAQ
What does VALERIO TX do?
Valerio Therapeutics SA is a is a clinical-stage biotechnology company, which engages in the development of oncology drugs targeting tumor intracellular processes. The company is headquartered in Paris, Ile-De-France and currently employs 25 full-time employees. The company went IPO on 2005-07-12. The firm targets tumor DNA functions through unparalleled mechanisms of action in the sought-after field of DNA damage response (DDR). The company aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. The company has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. The company also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.
What is the current price of ALVIO stock?
The current stock price of ALVIO.PA is 0.1584 EUR. The price increased by 1.67% in the last trading session.
Does ALVIO stock pay dividends?
ALVIO.PA does not pay a dividend.
What is the ChartMill rating of VALERIO TX stock?
ALVIO.PA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the ownership details for ALVIO stock?
You can find the ownership structure of VALERIO TX (ALVIO.PA) on the Ownership tab.